Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00092404
Status:
COMPLETED
Last Update Posted:
2017-03-15
First Post:
2004-09-22
Brief Title:
Safety Tolerability and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin rHA in Children 12 to 18 Months of Age V205C-009COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Comparison of the Safety Tolerability and Immunogenicity of V205C Manufactured With Recombinant Human Albumin rHA Versus V205C Manufactured With Pooled-Donor Human Serum Albumin HSA in Healthy Children 12 to 18 Months of Age
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this trial is to study the safety and immune response to measles mumps and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein
Detailed Description:
The duration of treatment is 6 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_074 | None | None | None |